Bandingkan Harga & Kinerja Menteng Heritage Realty Tbk. (HRME) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Menteng Heritage Realty Tbk. dan Organon Pharma Indonesia Tbk.: Menteng Heritage Realty Tbk. diperdagangkan di Rp45 (kapitalisasi pasar 268,14 M, volume 24 jam 1,93 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Menteng Heritage Realty Tbk. jauh lebih besar — sekitar 2,6× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| HRME | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 268,14 M | 104,4 M |
Volume | 1,93 jt | — |
Lot | 19,34 rb | — |
Perputaran | 86,7 jt | — |
Harga Rata-rata | 44,84 | — |
Nilai Transaksi | 86,7 jt | — |
Harga Ekuilibrium Indikatif | 45 | — |
Volume Ekuilibrium Indikatif | 1,08 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Menteng Heritage Realty Tbk.
PT Menteng Heritage Realty Tbk ("Company") was established under the name of PT Citra Prestasi Abadi based on Notarial Deed Rita Imelda Ginting, S.H., No. 27 dated June 28, 2007. The deed of establishment was approved by the Minister of Law and Human Rights of the Republic of Indonesia in the Letter Decree No. W7-09116 HT.01.01-TH.2007 dated August 20, 2007. The company changed its name from PT Citra Prestasi Abadi to PT Menteng Heritage Realty on October 5, 2007 based on Deed of Minutes No. 9 from Rita Imelda Ginting, S.H.
Selengkapnya di halaman HRME →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
